ArticleOncotarget2014

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Leila R Martins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.